Hot Investor Mandate: Taiwan Based VC Firm Invests Up to $6M in Global Life Science Companies with Taiwan Market Potential

19 Sep

A venture capital firm founded with headquarters in Taipei City, Taiwan, with additional partners based in Silicon Valley, Korea, Singapore, and Japan, formed a fund with local and international investors. The firm has the capacity to invest in companies they identify as a strong fit, with initial investments typically in the $1-6 M range. The firm is looking for companies globally but would prefer companies that have Taiwan angle.

The firm is an opportunistic investor that currently considering Therapeutics, Medical Devices, Diagnostics, Biotechnology R&D, and Healthcare IT companies. The firm is open to many sectors in therapeutics but prefers companies that are into phase I of clinical trials or later. The firm is open to medical devices with all FDA regulatory pathways, including 510k, PMA, and software-enabled device. The firm invest in any phases in medical devices and diagnostics with a preference for those with in human data. The firm looks into any indications except orphan disease.

The firm currently will invest in privately held companies only. The firm has no specific requirements for management team. The firm can participate as either lead or co-investor and generally requests a board seat or board observer rights in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm with USA and Asia Operations Invests in Novel Medical Devices, Diagnostics, and Digital Health Companies in USA and China

19 Sep

A venture capital firm with operations in the USA and Asia manages over $750 million in committed capital across 8 funds. The firm focuses on early stage companies in Technology and Healthcare sectors with an initial investment size ranging from $500k to $5M.The firm primarily looks to invest in companies based in China and US.

The firm is currently looking for new investment opportunities in Diagnostics, Medical Devices, Digital Health and Advanced Materials sectors. The firm is very opportunistic in terms of subsectors and indications, and is open to all classes of devices. The firm prefers to invest companies in pre-clinical and clinical stage, but it is open to consider companies with products on the market. Historically, the firm was active in companies developing diagnostic services and instrumentation, fetal monitoring and ultrasound systems, a stem cell bank, numerous health IT and vascular closure devices.

The firm invests in both private and public companies with a strong management team. The firm doesn’t have specific requirements for companies’ revenue or EBITDA. The firm looks to take a Board seat post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Private Investment Firm Seeking to Invest in Personal Medicine Diagnostics as well as Digital Health Technologies in USA & Canada

19 Sep

A private investment firm is looking to make venture investments in emerging fast growth projects. Typical equity investments range from $500,000 to $3 million per deal. The firm will invest in companies across the United States and Canada.

Currently, the firm is most interested in areas of personal medicine diagnostics, particularly in genomics and proteomics. Other areas of high interest include, digital health, platform technologies, nutrition, clean environment, and much more selectively drug development and medical devices. The firm has experience in immunology and is more familiar with vaccine and antibody based technologies. The firm is open in terms of indication and considers orphan indications as well but requires strong data and a clear pathway to exit.

The firm invests in privately held companies and will both lead or co-invest. The firm looks to take a board seat in some of its portfolio companies though it is not a requirement. The firm looks for smart and passionate management teams with high levels of experience in the field.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

From 38 Finalists, RESI Boston’s Audience Selects Innovation Challenge Champions

12 Sep

By Lucy Parkinson, VP of Investor Research, LSN

Yesterday’s RESI event brought together over 350 investors and over 350 startups in Boston’s Back Bay.  There were so many meetings that RESI Partnering filled to capacity.  LSN is delighted to have facilitated so many new connections, and we hope that these relationships continue to grow in the follow-up.

The RESI Innovation Challenge showcased 38 emerging startups in the biotech, medtech, diagnostics and digital health fields.  All the competitors brought novel, exciting discoveries to the technology showcase, selected by LSN’s Expert System and scientific review team.  RESI’s attendees chose the winners by using their RESI Cash tokens to cast votes for their favorite participants.  We would like to introduce you all to the 3 top placed companies, as selected by the RESI ecosystem.  Thank you, all, for taking part by casting your votes.

First Place: Zepto Life Technologies

Zepto, an in-vitro diagnostics company, features uniquely-accurate and multiplex-ready “lab-on-a-chip” technology – co-developed with the Mayo Clinic – to improve patient outcomes through superior assay performance at patients’ exact points of need (a $12B market). Zepto’s fully-automated lab-on-a-chip Immunoassay Platform can conveniently deliver “central lab-quality” performance almost anywhere. Initially, Zepto is working to equip ERs and ambulances with highly-sensitive Troponin assays, accelerating myocardial injury detection. Meanwhile, Zepto’s portable Liquid Biopsy Platform can detect 1% cancer gene mutation (eg. PIK3CA, EGFR, KRAS) and achieve unparalleled specificity of 99.9%+ in less than 2 hours. This can revolutionize the $6B tissue-based biopsy market. Zepto seeks $30M, primarily to launch the Immunoassay Platform with D-Dimer assays and complete PIK3CA-focused product development on the Liquid Biopsy Platform.

YongYong Zhang, CEO & Co-Founder, Zepto Life Technologies

 

Second Place: BOYDSense

BOYDSense, Inc. is a medical technology company providing non-invasive and affordable tools for measuring critical biomarkers via exhaled breath. Breath-based metabolomics focuses on the capture, identification, and quantification of volatile organic compound (VOC) biomarker patterns in human breath and using them to diagnose and monitor chronic diseases, such as diabetes. BOYDSense’s first commercial product, the g-Sense Breath Meter, is a hand-held breath meter that can accurately predict blood glucose values from breath VOC’s. The g-Sense meter does not need consumables, is wirelessly enabled, has a companion mobile application and a public API. The device design is lifestyle-friendly, pocket-sized, with a seamless user experience, allowing consumers to frequently measure blood glucose without the typical barriers of cost, pain, or social stigma.

Bruno Thuillier, CEO, BOYDSense

 

Third Place: Resmetrix Medical

Respiratory diseases are leading causes of death and disability in the world. More than 250 million people suffer from Chronic Obstructive Pulmonary disease (COPD) and 300 million from Asthma worldwide. Currently, respiratory deterioration is often detected too late, leading to sever exacerbation and complications, hospitalization and huge costs. Resmetrix is developing a wearable system (based on unique proprietary sensor built into a chest strap wirelessly connected to a smartphone app), that monitors at-risk respiratory patients in real-time, 24/7, anywhere, in any setting. Resmetrix system is the only system that detects small changes in a patient’s breathing pattern and provides immediate, early warning signs of deterioration in COPD patients at home, enable early window of intervention, early treatment and avoiding hospitalization.

Carmit Levy, Ph.D., CEO, Resmetrix Medical

RESI ASIA Innovation Challenge Deadline is Oct. 11th, 2019

Israeli Startups Make a Big Impact at RESI

12 Sep

By Karen Deyo, Senior Investor Research Analyst, LSN

Israel is frequently referred to as ‘The Startup Nation,’ with a lot of innovative technologies being developed in a multitude of sectors, including in healthcare. Over the past year, LSN has worked with the Israel Ministry of the Economy, the Israel Export Institute, the Israel Innovation Authority, the New England-Israel Business Council and several incubators and accelerators within Israel to bring these companies into the global RESI ecosystem.

In the 4 RESIs that have taken place so far in 2019, about 20 Israeli companies have been selected as finalists in the Innovation Challenge, with a few companies among the winners of these conferences. Yesterday, at RESI Boston, a group of these Israeli companies came to meet with the global investor attendees, including Novotalk, 1st place winner at RESI SF, PhotoPill Medical, 2nd place winner of RESI Europe, and Resmetrix, 3rd place winner yesterday. We look forward to seeing many more exciting companies from Israel at future RESIs, and hope that they will be as successful as the companies that have attended so far!

Izik Itzhakov of AEYE Health | Zohar Beeri of Novotalk | Ram Ben-Yehuda of PhotoPill Medical | Sharon Ben-Yehuda of PhotoPill Medical | Carmit Levy of Resmetrix Medical | Karen Deyo, Senior Investor Research Analyst, Life Science Nation

RESI Boston 2019 Westin Copley on September 11th – Check Out the Program Guide Now

5 Sep

By Nono Hu, Director of Marketing, LSN

It’s less than a week to go until RESI Boston, and we’re excited to share the digital RESI Program Guide with you!  Inside, you can take a look at our RESI Innovtion Challenge participants, investor panelists, exhibitors, and more.  If you want to know who’s making waves in the early stage life science world, look inside this guide.

We look forward to seeing you all next Wednesday at the Westin Copley Place for this one-day partnering and entrepreneurship extravaganza, RESI Boston 2019.

Hot Investor Mandate: USA VC Firm With Over $4B AUM Invests Up to $20M in New Therapeutics, Devices, and Digital Health Opportunities

5 Sep

A venture capital firm with multiple USA offices has managed over $4 billion in total assets across 11 funds and the firm focuses on making equity investments into the life science and technology spaces from seed to late venture stage. The investment size is varied, and typically it ranges from $1 million to $20 million. The firm will invest in companies primarily based in the US.An innovation arm of a global company nurtures innovative ideas developed internally and also forms external partnerships with startups in fields that are strategically relevant for the company’s business objectives. These partnerships may include co-development, in-kind services and/or early stage financial investments. The firm partners with startups based anywhere in the world.

The firm is currently looking for new opportunities in the Biotech Therapeutics, Medical Devices and Digital Health sectors. The firm will also consider Diagnostics, but that will not be its focus. For Therapeutics and Medical Devices, the firm is extremely opportunistic in terms of subsectors and indications. The firm is interested in companies targeting orphan diseases. The firm is generally looking for companies in the pre-clinical stage of development, but it also considers companies that may already have performed clinical studies, as well as companies near commercial stages dependent on the case.

The firm primarily invests in private companies, and considers pre-revenue companies. The firm doesn’t have specific requirements for company’s management team or revenue.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →